全文获取类型
收费全文 | 1682篇 |
免费 | 134篇 |
国内免费 | 104篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 99篇 |
妇产科学 | 15篇 |
基础医学 | 200篇 |
口腔科学 | 4篇 |
临床医学 | 98篇 |
内科学 | 274篇 |
皮肤病学 | 40篇 |
神经病学 | 35篇 |
特种医学 | 14篇 |
外国民族医学 | 1篇 |
外科学 | 140篇 |
综合类 | 270篇 |
预防医学 | 34篇 |
眼科学 | 9篇 |
药学 | 327篇 |
中国医学 | 107篇 |
肿瘤学 | 250篇 |
出版年
2023年 | 22篇 |
2022年 | 25篇 |
2021年 | 32篇 |
2020年 | 44篇 |
2019年 | 46篇 |
2018年 | 64篇 |
2017年 | 50篇 |
2016年 | 46篇 |
2015年 | 50篇 |
2014年 | 84篇 |
2013年 | 133篇 |
2012年 | 75篇 |
2011年 | 103篇 |
2010年 | 65篇 |
2009年 | 62篇 |
2008年 | 80篇 |
2007年 | 77篇 |
2006年 | 56篇 |
2005年 | 55篇 |
2004年 | 65篇 |
2003年 | 56篇 |
2002年 | 73篇 |
2001年 | 60篇 |
2000年 | 51篇 |
1999年 | 40篇 |
1998年 | 31篇 |
1997年 | 26篇 |
1996年 | 29篇 |
1995年 | 24篇 |
1994年 | 27篇 |
1993年 | 20篇 |
1992年 | 14篇 |
1991年 | 16篇 |
1990年 | 8篇 |
1989年 | 8篇 |
1988年 | 20篇 |
1987年 | 18篇 |
1986年 | 8篇 |
1985年 | 20篇 |
1984年 | 35篇 |
1983年 | 12篇 |
1982年 | 16篇 |
1981年 | 15篇 |
1980年 | 11篇 |
1979年 | 15篇 |
1978年 | 7篇 |
1977年 | 11篇 |
1976年 | 5篇 |
1975年 | 2篇 |
1973年 | 6篇 |
排序方式: 共有1920条查询结果,搜索用时 31 毫秒
41.
The field of pharmacogenomics was initiated in the 1950s and began to thrive after the completion of the human genome project 10 years ago. Thus far, more than 100 drug labels and clinical guidelines referring to pharmacogenomic biomarkers have been published, and several key pharmacogenomic markers for either drug safety or efficacy have been identified and subsequently adopted in clinical practice as pre-treatment genetic tests. However, a tremendous variation of genetic backgrounds exists between different ethnic groups. The application of pharmacogenomics in the Chinese population is still a long way off, since the published guidelines issued by the organizations such as US Food and Drug Administration require further confirmation in the Chinese population. This review highlights important pharmacogenomic discoveries in the Chinese population and compares the Chinese population with other nations regarding the pharmacogenomics of five most commonly used drugs, ie, tacrolimus, cyclosporine A, warfarin, cyclophosphamide and azathioprine. 相似文献
42.
目的 利用单一荧光试剂吖啶橙(acridine orange, AO)和简单的单激光流式细胞仪计数骨髓嗜多染红细胞细胞的微核率,达到了解化合物诱导微核作用的目的。方法 采用经典的染色体断裂剂环磷酰胺(cyclophosphamide, CP)腹腔注射小鼠和大鼠,24h后采集骨髓细胞,经过固定和吖啶橙(acridine orange, AO)荧光染色,利用单激光流式细胞仪计数微核,计数结果用WinDMI软件进行分析,作出等高图并设置窗口。结果 随着CP浓度的增高,骨髓细胞的含微核的嗜多染红细胞(micronucleated PCE, MNPCE)也相应增多,呈良好的量效关系。实验结果同时和手工计数比较,没有显著差异。结论 采用单一荧光染色(AO染色)和单激光流式细胞仪快速初筛化合物诱导微核作用是可靠的,较传统的手工方法更为灵敏,并节省了大量时间和成本,操作也更为简单。 相似文献
43.
44.
《Autoimmunity》2013,46(7):429-438
AbstractB-lymphocytes play a pivotal role in ANCA-associated vasculitides (AAV). The homeostasis of peripheral human B-lymphocyte subpopulations is tightly regulated, but may be disturbed in autoimmune disease or following immunosuppressive therapies. To elucidate the effect of immunosuppression and the relevance of B-lymphocyte disturbances, the B-lymphocyte compartment was analysed in 61 AAV patients. After immunosuppressive treatment a general B-lymphocytopenia developed in AAV patients. Within the B-lymphocyte subpopulations transitional B cells are the first maturation stage found in the peripheral blood. Transitional B-lymphocytes were significantly lower in AAV patients after immunosuppressive therapy compared to healthy controls. Furthermore, marginal zone B cells – a B-lymphocyte population protecting against encapsulated bacteria -- were markedly lowered after immunosuppressive therapy in AAV patients. AAV patients treated with immunosuppressants had lower numbers of naïve and memory B-lymphocytes. Numbers of marginal zone B cells, memory B cells and plasmablasts correlated with concentrations of immunoglobulins. We evaluated plasmablasts for a potential correlation with disease activity. Different from what has been reported for e.g. large vessel vasculitis, absolute numbers of plasmablasts were not increased in patients with AAV and showed no correlation to disease activity. As low transitional B cells after treatment with immunosuppressants indicated an impaired early B-lymphocyte development, seven patients treated with the B cell depleting agent rituximab (RTX) because of relapsing disease activity were analysed for their B cell repopulation kinetics. In the majority of these patients repopulation of the peripheral B cell compartment by newly formed transitional B cells after RTX treatment was constricted and delayed. 相似文献
45.
《Immunopharmacology and immunotoxicology》2013,35(4):562-568
Introduction:?Because dysfunction of the B-cell compartment is thought to be important in the pathogenesis of systemic lupus erythematosus (SLE), there has been a recent focus on therapies that target humoral immunity via multiple mechanisms. The aim of this paper was to demonstrate the importance of immunomonitoring in two cases with class II lupus nephritis on steroids who presented with a flare-up of disease. After a thorough work-up for infectious triggers of disease activity, conversion to another histopathological class of lupus nephritis was suspected. Deterioration of the patients’ clinical condition made kidney biopsy impossible, and as B-cell targeted therapy was considered, we decided to perform an immunophenotypic analysis and to tailor therapy to the results of the lymphocyte profile. As we incidentally found extremely low B-cell counts, any B-cell–targeted therapy was prohibited, and cyclophosphamide (Cy) was considered a viable therapeutic option.Methods:?We performed flow-cytometric lymphocyte (Ly) phenotyping (CD19, CD3, CD3CD4, CD3CD8, CD56/16) on two patients with class II lupus nephritis before and after two intravenous (i.v.) Cy pulse administrations. During all this time, patients were on steroids.Results:?Both patients showed extreme B-cell lymphopenia, a marker of active SLE, which was not greatly impacted by the treatment over the follow-up period.Conclusions:?As current therapies are aimed at targeting the B cell, an important component of adaptive immunity, caution must be exercised before their use. In addition, monitoring of Ly subsets is essential due to the occurrence of extreme B-cell lymphopenia. 相似文献
46.
淫羊藿苷调节雄性大鼠生殖功能 总被引:2,自引:0,他引:2
目的:探讨淫羊藿苷在环磷酰胺诱导的大鼠睾丸生精障碍动物模型中的作用,研究淫羊霍苷对睾丸功能的影响.方法:分为空白对照组、阴性对照组、模型组、淫羊藿苷治疗组;H-E染色观察睾丸组织结构变化,TUNEL方法检测睾丸生殖细胞凋亡,放射免疫法检测血清睾酮.结果:睾丸H-E染色切片观察显示模型组睾丸生精小管直径缩小,间距增宽,生精上皮变薄,生殖细胞数量减少,生精小管多未见精子形成,与空白对照组比较其生精小管结构变化显著;淫羊藿苷治疗组与模型组比较生精小管壁增厚,含有精子的生精小管明显增多.睾丸生精小管中生殖细胞凋亡的观察模型组与空白对照组比较其生殖细胞凋亡增多,变化显著;淫羊藿苷治疗组与模型组比较生精小管中生殖细胞凋亡数量明显减少.模型组与空白对照组比较血清睾酮明显降低;淫羊藿苷治疗组与模型组比较其血清睾酮明显增加.结论:淫羊藿苷对环磷酰胺诱导生精障碍的睾丸具有改善睾丸生精小管结构、减少生殖细胞凋亡、促进精子发生和间质细胞分泌睾酮的功能. 相似文献
47.
《Biology of blood and marrow transplantation》2013,19(10):1430-1438
Administration of cyclophosphamide after transplantation (post-transplantation cyclophosphamide, PTC) has shown promise in the clinic as a prophylactic agent against graft-versus-host disease (GVHD). An important issue with regard to recipient immune function and reconstitution after PTC is the extent to which, in addition to diminution of antihost allo-reactive donor T cells, the remainder of the nonhost allo-reactive donor T cell pool may be affected. To investigate PTC's effects on nonhost reactive donor CD8 T cells, ova-specific (OT-I) and gp100-specific Pmel-1 T cells were labeled with proliferation dyes and transplanted into syngeneic and allogeneic recipients. Notably, an intermediate dose (66 mg/kg) of PTC, which abrogated GVHD after allogeneic HSCT, did not significantly diminish these peptide-specific donor T cell populations. Analysis of the rate of proliferation after transplantation illustrated that lymphopenic-driven, donor nonhost reactive TCR Tg T cells in syngeneic recipients underwent slow division, resulting in significant sparing of these donor populations. In contrast, after exposure to specific antigens at the time of transplantation, these same T cells were significantly depleted by PTC, demonstrating the global susceptibility of rapidly dividing T cells after an encounter with cognate antigen. In total, our results, employing both syngeneic and allogeneic minor antigen-mismatched T cell replete models of transplantation, demonstrate a concentration of PTC that abrogates GVHD can preserve most cells that are dividing because of the accompanying lymphopenia after exposure. These findings have important implications with regard to immune function and reconstitution in recipients after allogeneic hematopoietic stem cell transplantation. 相似文献
48.
49.
Jan A.J.G. van den Brand Peter R. van Dijk Julia M. Hofstra Jack F.M. Wetzels 《Clinical journal of the American Society of Nephrology》2014,9(6):1066-1073
Background and objectives
Cyclophosphamide treatment improves renal survival in patients with idiopathic membranous nephropathy. However, use of cyclophosphamide is associated with cancer. The incidence of malignancies in patients with idiopathic membranous nephropathy was evaluated, and the cancer risk associated with cyclophosphamide use was estimated.Design, setting, participants, & measurements
Patients who attended the clinic were included prospectively from 1995 on. A crude incidence ratio for the occurrence of malignancy was calculated. Incidence ratios were subsequently standardized to potential confounders. Latency between cyclophosphamide therapy and the occurrence of cancer was estimated by stratifying for time since the start of treatment. Finally, Poisson regression was used to obtain a multiple adjusted incidence ratio and investigate the dose–response relationship between cyclophosphamide and cancer.Results
Data were available for 272 patients; the mean age was 51 years, and 70% of the patients were men. Median follow-up was 6.0 years (interquartile range=3.6–9.5), and 127 patients were treated with cyclophosphamide. Cancer incidence was 21.2 per 1000 person-years in treated patients compared with 4.6 per 1000 person-years in patients who did not receive cyclophosphamide, resulting in crude and adjusted incidence ratios of 4.6 (95% confidence interval, 1.5 to 18.8) and 3.2 (95% confidence interval, 1.0 to 9.5), respectively.Conclusion
Cyclophosphamide therapy in idiopathic membranous nephropathy gives a threefold increase in cancer risk. For the average patient, this finding translates into an increase in annual risk from approximately 0.3% to 1.0%. The increased risk of malignancy must be balanced against the improved renal survival. 相似文献50.
Heiko Rühl Lars Schröder Jens Müller Rolf Fimmers Shorena Sukhitashvili Julia Welz Walther C. Kuhn Johannes Oldenburg Christian Rudlowski Bernd Pötzsch 《Thrombosis research》2014